- Home
- SCNX vs ITRM Comparison
SCNX vs ITRM Comparison
Compare SCNX & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- ITRM
- Stock Information
- Founded
- SCNX 2010
- ITRM 2015
- Country
- SCNX United States
- ITRM Ireland
- Employees
- SCNX N/A
- ITRM N/A
- Industry
- SCNX Other Pharmaceuticals
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- ITRM Health Care
- Exchange
- SCNX Nasdaq
- ITRM Nasdaq
- Market Cap
- SCNX 14.4M
- ITRM 40.0M
- IPO Year
- SCNX 2020
- ITRM 2018
- Fundamental
- Price
- SCNX $1.18
- ITRM $0.98
- Analyst Decision
- SCNX
- ITRM Strong Buy
- Analyst Count
- SCNX 0
- ITRM 2
- Target Price
- SCNX N/A
- ITRM $7.00
- AVG Volume (30 Days)
- SCNX 133.2K
- ITRM 492.4K
- Earning Date
- SCNX 08-10-2025
- ITRM 08-13-2025
- Dividend Yield
- SCNX N/A
- ITRM N/A
- EPS Growth
- SCNX N/A
- ITRM N/A
- EPS
- SCNX N/A
- ITRM N/A
- Revenue
- SCNX $146,901.00
- ITRM N/A
- Revenue This Year
- SCNX N/A
- ITRM N/A
- Revenue Next Year
- SCNX N/A
- ITRM $270.19
- P/E Ratio
- SCNX N/A
- ITRM N/A
- Revenue Growth
- SCNX N/A
- ITRM N/A
- 52 Week Low
- SCNX $0.69
- ITRM $0.81
- 52 Week High
- SCNX $23.77
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- ITRM 45.38
- Support Level
- SCNX N/A
- ITRM $0.93
- Resistance Level
- SCNX N/A
- ITRM $1.03
- Average True Range (ATR)
- SCNX 0.00
- ITRM 0.05
- MACD
- SCNX 0.00
- ITRM 0.00
- Stochastic Oscillator
- SCNX 0.00
- ITRM 17.48
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.